A new study led by researchers at Mass General Brigham suggests a nasal spray developed to target neuroinflammation could one day be an effective treatment for traumatic brain injury (TBI).

The FDA cleared the investigational new drug application for LTZ-301, a first-in-class myeloid engager immunotherapy, with a ...

REDWOOD CITY, CA, USA & SHENZHEN, China I4, 2025 I LTZ Therapeutics, an immunotherapy-focused biotech company, today announced that the U.S.